Jason Zemansky is ranked #2367 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Jason Zemansky

BofA

Jason Zemansky

Q: How accurate are Jason Zemansky's stock ratings?

About 48% of Jason's ratings were profitable over a one-year hold, with an average return of +5.2% per rating, measured by 13Foresight from historical prices.

Bank of America Securities

Wall Street Analyst

★★☆☆☆

#2367

on 13Foresight · ranked by our own returns

48%

Success Rate

+5.2%

Average Return

40 of 83 calls profitable · +22.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 48% of Jason Zemansky's ratings turned a profit when each position was held for 1 year — averaging +5.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

116 Buy 56 Hold 10 Sell

Jason's Stock Coverage 22 ratings · 2026-09-27

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
TVTX Travere Therapeutics	Sep 23, 2026	BUY	Strong Buy -2.1% avg upside 22 analysts	$71.00 19.43% Upside	-0.7%	·
LGND Ligand Pharma	Sep 22, 2026	BUY	Strong Buy -8.4% avg upside 16 analysts	$388.00 28.73% Upside	+1.0%	·
INSM Insmed	Sep 21, 2026	BUY	Strong Buy +47.4% avg upside 37 analysts	$214.00 81.61% Upside	+0.4%	·
ABOS Acumen Pharmaceuticals	Sep 17, 2026	BUY	Strong Buy +267.1% avg upside 10 analysts	$8.00 257.12% Upside	-10.3%	·
RCKT Rocket Pharmaceuticals	Sep 15, 2026	BUY	Buy +527.6% avg upside 30 analysts	$10.00 285.44% Upside	-1.2%	·
TYRA Tyra Bioscience	Sep 08, 2026	BUY	Strong Buy +100.8% avg upside 17 analysts	$39.00 79.28% Upside	-18.6%	·
CYTK Cytokinetics	Aug 31, 2026	HOLD	Strong Buy +40.4% avg upside 36 analysts	$85.00 31.48% Upside	-7.4%	·
KURA Kura Oncology	Aug 13, 2026	BUY	Strong Buy +141.6% avg upside 26 analysts	$31.00 188.05% Upside	+15.0%	·
BBIO BridgeBio Pharma	Aug 11, 2026	BUY	Strong Buy +45.3% avg upside 34 analysts	$104.00 58.53% Upside	-22.1%	·
RCUS Arcus Biosciences	Aug 11, 2026	HOLD	Strong Buy +42.7% avg upside 21 analysts	$29.00 16.17% Upside	-15.0%	·
KROS Keros Therapeutics	Aug 11, 2026	HOLD	Strong Buy +105.8% avg upside 21 analysts	$17.00 46.30% Upside	+8.6%	·
LYEL Lyell Immunopharma	Aug 11, 2026	SELL	Strong Buy +181.5% avg upside 12 analysts	$12.00 21.84% Upside	+33.8%	·
SNDX Syndax Pharmaceuticals	Aug 05, 2026	BUY	Strong Buy +92.3% avg upside 27 analysts	$26.00 42.79% Upside	-8.6%	·
MDGL Madrigal Pharmaceuticals	Jul 30, 2026	HOLD	Strong Buy -0.3% avg upside 34 analysts	$543.00 5.15% Upside	+3.9%	·
BIIB Biogen	Jul 29, 2026	HOLD	Strong Buy +12.1% avg upside 53 analysts	$219.00 3.70% Downside	+8.8%	·
IKT Inhibikase Therapeutics	Jul 27, 2026	BUY	Strong Buy +191.0% avg upside 8 analysts	$6.00 191.27% Upside	-2.1%	·
EIKN Eikon Therapeutics, Inc.	Jun 03, 2026	BUY	Buy +213.1% avg upside 5 analysts	$32.00 304.05% Upside	-16.0%	·
HOWL Werewolf Therapeutics	Feb 17, 2026	BUY	Strong Buy +618.8% avg upside 8 analysts	$7.00 629.20% Upside	+48.9%	·
BMRN BioMarin Pharmaceutical	Oct 30, 2024	BUY	Strong Buy +59.0% avg upside 52 analysts	—	-22.1%	·
OKUR OnKure Therapeutics	Mar 28, 2024	SELL	Strong Buy +662.1% avg upside 13 analysts	$12.00 313.78% Upside	+73.1%	·
KLRS Kalaris Therapeutics	Dec 26, 2023	SELL	Strong Buy +336.6% avg upside 13 analysts	$1.00 65.82% Downside	+37.0%	·
QTTB Q32 Bio	Nov 17, 2023	HOLD	Buy +561.6% avg upside 26 analysts	—	+226.9%	·

🔒 17 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Jason Zemansky — Frequently Asked Questions

How accurate are Jason Zemansky's stock ratings?

Based on the calls 13Foresight could measure, about 48% of Jason's ratings were profitable over a one-year hold, with an average return of +5.2% per rating, or +19.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Jason ranked on 13Foresight?

Jason Zemansky is currently ranked #2367 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Jason cover?

Jason most recently has ratings on TVTX, LGND, INSM, ABOS, RCKT, TYRA, CYTK, KURA, BBIO, RCUS, KROS, LYEL and 10 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Jason Zemansky

Rating Distribution

Welcome to 13Foresight!